JP2023527411A - がん細胞の負荷を減少させ、正常な造血を保護するための化合物および方法 - Google Patents

がん細胞の負荷を減少させ、正常な造血を保護するための化合物および方法 Download PDF

Info

Publication number
JP2023527411A
JP2023527411A JP2022573207A JP2022573207A JP2023527411A JP 2023527411 A JP2023527411 A JP 2023527411A JP 2022573207 A JP2022573207 A JP 2022573207A JP 2022573207 A JP2022573207 A JP 2022573207A JP 2023527411 A JP2023527411 A JP 2023527411A
Authority
JP
Japan
Prior art keywords
inhibitor
cancer
group
groups
selectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527411A5 (enExample
Inventor
ジョン エル． マグナニ，
ウィリアム イー． フォグラー，
Original Assignee
グリコミメティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリコミメティクス， インコーポレイテッド filed Critical グリコミメティクス， インコーポレイテッド
Publication of JP2023527411A publication Critical patent/JP2023527411A/ja
Publication of JP2023527411A5 publication Critical patent/JP2023527411A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022573207A 2020-05-31 2021-05-28 がん細胞の負荷を減少させ、正常な造血を保護するための化合物および方法 Pending JP2023527411A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063032675P 2020-05-31 2020-05-31
US63/032,675 2020-05-31
US202063060595P 2020-08-03 2020-08-03
US63/060,595 2020-08-03
US202063063892P 2020-08-10 2020-08-10
US63/063,892 2020-08-10
US202063198864P 2020-11-18 2020-11-18
US63/198,864 2020-11-18
PCT/US2021/034773 WO2021247396A1 (en) 2020-05-31 2021-05-28 Compounds and methods for reduction of cancer cell burden and protection of normal hematopoiesis

Publications (2)

Publication Number Publication Date
JP2023527411A true JP2023527411A (ja) 2023-06-28
JP2023527411A5 JP2023527411A5 (enExample) 2024-06-05

Family

ID=76624176

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573207A Pending JP2023527411A (ja) 2020-05-31 2021-05-28 がん細胞の負荷を減少させ、正常な造血を保護するための化合物および方法

Country Status (5)

Country Link
US (1) US20230165882A1 (enExample)
EP (1) EP4157285A1 (enExample)
JP (1) JP2023527411A (enExample)
CN (1) CN115666584A (enExample)
WO (1) WO2021247396A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016536300A (ja) * 2013-10-31 2016-11-24 バイオカイン セラピューティックス リミテッド Ｆｌｔ３変異を有する急性骨髄性白血病の治療方法
JP2019524791A (ja) * 2016-08-08 2019-09-05 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2264043T1 (en) 2005-09-02 2018-01-31 Glycomimetics, Inc. HETEROBIFUNCTIONAL PAN-SELECTINE INHIBITORS
AU2008336249B2 (en) 2007-12-10 2015-01-29 The University Of Queensland Treatment and prophylaxis
AU2010241807B2 (en) 2009-05-01 2014-08-14 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
EP2794626B3 (en) 2011-12-22 2020-08-05 GlycoMimetics, Inc. E-selectin antagonist compounds
CN107108679B (zh) 2014-12-03 2020-10-23 糖模拟物有限公司 E-选择蛋白和cxcr4趋化因子受体的异双官能抑制剂
EP3383882A1 (en) 2015-12-02 2018-10-10 GlycoMimetics, Inc. Heterobifunctional pan-selectin antagonists having a triazole linker
BR112019006642A2 (pt) 2016-10-07 2019-07-02 Glycomimetics Inc antagonistas multiméricos de e-selectina altamente potentes
US11548908B2 (en) 2017-12-29 2023-01-10 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
CA3136661A1 (en) 2019-04-24 2020-10-29 Glycomimetics, Inc. Galactose-linked multimeric glycomimetic inhibitors of e-selectins, galectin-3, and/or cxcr4 chemokine receptors
US20220220144A1 (en) 2019-04-24 2022-07-14 Glycomimetics, Inc. Multimeric pan-selectin antagonists
CN114341368A (zh) 2019-07-12 2022-04-12 糖模拟物有限公司 使用基因表达作为多种肿瘤类型的e-选择素抑制剂功效和临床结果的指标的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016536300A (ja) * 2013-10-31 2016-11-24 バイオカイン セラピューティックス リミテッド Ｆｌｔ３変異を有する急性骨髄性白血病の治療方法
JP2019524791A (ja) * 2016-08-08 2019-09-05 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ

Also Published As

Publication number Publication date
CN115666584A (zh) 2023-01-31
US20230165882A1 (en) 2023-06-01
WO2021247396A1 (en) 2021-12-09
EP4157285A1 (en) 2023-04-05

Similar Documents

Publication Publication Date Title
CN109890421B (zh) 高效的多聚体e-选择蛋白拮抗剂
DK2794626T3 (en) E-selectin antagonist compounds
CA2746551C (en) E-selectin antagonists for treating an immunocompromised condition
JP7195283B2 (ja) Ｔ細胞前リンパ球性白血病の処置への使用のためのチノスタムスチン
US20090312278A1 (en) Treatment of cancers of the blood using selected glycomimetic compounds
Dolgova et al. Efficacy of the new therapeutic approach in curing malignant neoplasms on the model of human glioblastoma
JP2023529485A (ja) Ｅ－セレクチン標的化を介して微小環境媒介耐性を克服するための組成物および方法
US20230165882A1 (en) Compounds and methods for reduction of cancer cell burden and protection of normal hematopoiesis
TWI753178B (zh) Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物
US20240269157A1 (en) Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting
JP2022526210A (ja) がんの処置のための方法および組成物
US20230167149A1 (en) Cd33 ligands suitable for incorporation into carriers
WO2023008459A1 (ja) 癌の治療及び／又は予防のための医薬品
US10550130B2 (en) Benzo-thiazolo-imidazole compounds and uses thereof
KR102558989B1 (ko) 항암 화학요법으로 인한 내성을 완화하고 항암 화학요법의 효과를 증진시키기 위한 약학적 조성물 및 그 용도
CA3099702A1 (en) Selection of patients for combination therapy
RU2792057C2 (ru) Комбинация ингибитора mcl-1 и стандартного лекарственного препарата для лечения гематологических злокачественных новообразований, её применение и содержащие её фармацевтические композиции
HK40025641B (en) Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
KR20250054778A (ko) 암의 치료 및/또는 예방을 위한 의약품
CN118555959A (zh) 心脏保护方法
HK40025641A (en) Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
Podolski et al. INFLUENCE OF TREATMENT WITH AREDIA (PAMIDRO-NAT ON THE SKELETAL METASTASES FROM BREAST CANCER
OA19591A (en) Combination of a Mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof.
HK1201842B (en) E-selectin antagonist compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250529

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251121